Skip to content

Clinical Study To Assess The Efficacy of Ayurvedic Formulations In PCOS

A Randomized Control Open Label Clinical Trial On The Efficacy Of Shatapushpa Churna And Madhutailika Basti In Nashtartava w.s.r. To Polycystic Ovarian Syndrome

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026410
Enrollment
30
Registered
2020-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N830- Follicular cyst of ovary

Interventions

Intervention1: Group A Shatapushpa Churna: Shatapushpa Churna 6gm orally with Ghrita twice a day for a period of 90 days or 3 consecutive cycles. Control Intervention1: Group B Madhutailika Basti: Mad

Sponsors

National Institute of Ayurveda Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to give voluntary informed consent. Both married and unmarried patients. ASRM/ESHRE (Rotterdam) Criteria,2013- Affected individuals must have two out of three criteria 1. Oligo and /or anovulation 2. Hyperandrogenism (clinical and /or biochemical). 3. Polycystic ovaries(Confirmed on USG).

Exclusion criteria

Exclusion criteria: Patients not willing to give voluntary informed consent. Women of age 40years. Patients with chronic systemic illness (Congestive cardiac failure, Hypertension, cirrhosis of liver, chronic renal disease, diabetes mellitus, Tuberculosis etc.). Patients using oral contraceptive pills. Patients with any organic reproductive system abnormalities (Excluded clinically and radiologically), pelvic inflammatory disease, hydrosalpinx, endometriosis, adenomyosis, fibroid uterus, carcinoma of reproductive organ. Any type of malignancy. Patients with positive Sexually transmitted diseases (STDs), Human Immunodeficiency Virus HIV, Hepatitis B Surface Antigen(HbsAg). Patients suffering from adrenal hyperplasia, severe insulin resistance, androgen secreting neoplasm, thyroid abnormalities, Cushingâ??s syndrome.

Design outcomes

Primary

MeasureTime frame
Changes in features of oligomenorrhoea /anovulation.Timepoint: 3 months

Secondary

MeasureTime frame
Changes in PCOS features (i.e. acne, hirsutism).Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Shalvi Sharma

National Institute of Ayurveda, Jaipur

baruhunt@gmail.com9982678508

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026